Shape Therapeutics Unveils Major Advances in AI-Powered Platform for Precision RNA Editing
October 03, 2024 13:05 ET
|
Shape Therapeutics, Inc.
Shape Therapeutics, a leader in RNA-based gene therapy, today released two preprint manuscripts detailing major technological breakthroughs.
Shape Therapeutics Appoints Healthcare Industry Leaders David Epstein and Todd Simpson to its Board of Directors
June 25, 2024 09:00 ET
|
Shape Therapeutics, Inc.
Shape Therapeutics Appoints Healthcare Industry Leaders David Epstein and Todd Simpson to its Board of Directors
Shape Therapeutics RNAfix® Editing Platform Achieves >90% Editing in Mouse and Non-Human Primate Brain
May 08, 2024 09:31 ET
|
Shape Therapeutics, Inc.
RNAfix achieves up to 92% editing in the non-human primate brain after AAV-based gRNA delivery RNAfix achieves >95% editing throughout the mouse brain with sustained durability at least 6 months...
Shape Therapeutics Announces Appointment of Matt Valentino as Chief People Officer
May 02, 2024 08:00 ET
|
Shape Therapeutics, Inc.
SEATTLE, May 02, 2024 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (ShapeTX), a leader at the convergence of AI and RNA editing to revolutionize genomic medicine, is pleased to announce the...
Shape Therapeutics to Showcase RNA Editing in the Brain and Validation of their Stable AAV Producer Cell Line at ASGCT 2024
April 30, 2024 08:00 ET
|
Shape Therapeutics, Inc.
SEATTLE, April 30, 2024 (GLOBE NEWSWIRE) -- Shape Therapeutics, a leader at the convergence of AI and RNA editing to revolutionize genomic medicine, today announced its upcoming oral presentations...
ShapeTX Expands Strategic Collaboration with Roche with Addition of a New Target
November 30, 2023 08:00 ET
|
Shape Therapeutics, Inc.
ShapeTX announces the expansion of its drug discovery partnership with Roche with new target
Otsuka collaborates with ShapeTX to develop novel AAV gene therapies for ocular diseases
September 07, 2023 17:00 ET
|
Shape Therapeutics, Inc.; Otsuka
TOKYO and SEATTLE, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Otsuka Pharmaceutical Co., Ltd. (Otsuka) and ShapeTX, the programmable medicine company using AI and RNA to end genetic diseases, today announce...
ShapeTX Announces the Appointment of Adrian W. Briggs, Ph.D. As Chief Technology Officer
June 20, 2023 08:00 ET
|
Shape Therapeutics, Inc.
SEATTLE, June 20, 2023 (GLOBE NEWSWIRE) -- ShapeTX, the programmable medicine company using AI and RNA to end genetic diseases, today announced the appointment of Adrian W. Briggs, Ph.D. as Chief...
ShapeTX Announces Seven Presentations at ASGCT 2023 Showcasing the Potential of Generative AI and RNA in CNS Disorders and Beyond
May 04, 2023 08:00 ET
|
Shape Therapeutics, Inc.
SEATTLE, May 04, 2023 (GLOBE NEWSWIRE) -- ShapeTX, the programmable medicine company using AI and RNA to end genetic diseases, today announced seven presentations from across its technology...
ShapeTX to Showcase Groundbreaking Advances in CNS in vivo RNA Editing, CNS-Targeting AAVs, and TruStable™ AAV Manufacturing at the J.P. Morgan 41st Annual Healthcare Conference
January 05, 2023 08:00 ET
|
Shape Therapeutics, Inc.
SEATTLE, Jan. 05, 2023 (GLOBE NEWSWIRE) -- ShapeTX today announced Francois Vigneault, Ph.D., Co-founder and Chief Executive Officer, will present at the J.P. Morgan 41st Annual Healthcare...